Non-Viral Gene Delivery – VJRegenMed

The changing landscape of hospital-based cell and gene therapy manufacturing

Simon Ng — Thu, 27 Jan 2022 18:00:58 +0000

Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, discusses the evolving space of hospital-based cell and gene therapy (CGT) manufacturing. Cell and gene therapies are being developed very quickly to meet the growing demand in healthcare and there are ongoing efforts to make these therapies more accessible and affordable for patients. Mr Roumeliotis talks on the breadth of the CGT space, as well as promising non-viral vector and allogeneic cell therapies. He additionally highlights the role of Orgenesis in accelerating the manufacturing process of cell and gene therapies, increasing the availability of know-how and technology to stakeholders. This interview took place at Advanced Therapies Week 2022.

Medical Grade Molecular Rebar: a unique nanoparticle delivery vehicle

Simon Ng — Thu, 27 Jan 2022 17:03:31 +0000

Kurt Swogger, CEO, BioPact Ventures, Austin, TX, talks on the development, manufacturing process, and advantages of BioPact’s Medical Grade Molecular Rebar (MGMR) technology, a carbon nanotube designed to deliver a wide range of therapeutics to cells. These nanotubes are remarkably safe and can easily penetrate cells without causing damage. MGMR can be loaded with a variety of cargos depending on the surfactant on the surface of the tube. In addition, MGMR’s simple manufacturing process results in faster delivery of products to patients than with viral vectors. Mr Swogger explains that BioPact is currently looking for partners to develop this technology. This interview took place at Advanced Therapies Week 2022.

Non-viral gene delivery & gene editing: highlights from ESGCT

admin_vjr_user — Fri, 31 Dec 2021 10:38:53 +0000

Ralf Schmid, PhD, MSCR, University of Pennsylvania, Philadelphia, PA, describes some of his highlights from the European Society of Gene & Cell Therapy (ESGCT) Virtual Congress 2021, which included important basic and translational research in cell and gene therapies. Dr Schmid discusses advances seen in non-viral delivery strategies for gene therapies following lessons learned from the development of the COVID-19 vaccine. He also explains that much progress has been made in gene editing during the pandemic including the development of new strategies for improving safety and efficacy of gene editing, which hold promise for the treatment of brain disorders in the future. This interview took place at the ESGCT Virtual Congress 2021.

The current landscape of advanced therapies in the UK

admin_vjr_user — Wed, 13 Oct 2021 17:11:09 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, provides an overview of the current state of the cell and gene therapies industry in the UK and outlines some of the key areas of ongoing development. He highlights the research and investment in chimeric antigen receptor (CAR) T-cell therapies, gene therapies, RNA-based therapies, as well as non-viral gene delivery technologies. Cell-delivered therapeutics utilizing induced pluripotent stem cell (iPSC) technology to deliver gene therapies to patients are currently under investigation. This interview took place at the Advanced Therapies Congress & Expo 2021.